ICF004

ICF004 is an investigational inhaled powder formulation of **epigallocatechin gallate (EGCG)**, currently being evaluated in a Phase 1 clinical trial for its pharmacokinetics and safety in both healthy volunteers and patients with **interstitial lung disease (ILD)**. The study uses single-dose administration at varying inhaled doses (4mg, 8mg, 12mg), compared against an oral EGCG comparator arm (Teavigo 600mg), with pharmacokinetic and safety endpoints including blood sampling and bronchoalveolar lavage to assess pulmonary and systemic drug exposure. The primary goal is to establish foundational pharmacokinetic data and the safety profile of inhaled EGCG in ILD, compared to oral dosing[1][2][4].